According to U.S. News, Trinity Health has reached, at least in principle, a hepatitis C lawsuit settlement that has been pending in North Dakota. The plaintiffs’ attorney, Behdad Sadeghi, indicated that the settlement involving 21 of the victims still needed to be finalized. Even so, attorneys for Trinity filed a motion to dismiss the lawsuit
Taxotere (docetaxel) is a drug that is manufactured by Sanofi-Aventis for use in treating a number of different types of cancer. In 2004, the Food and Drug Administration, FDA, approved Taxotere for the treatment of breast cancer. It has since been discovered that Taxotere can cause permanent hair loss. An expected side effect of cancer
Just last week, Mylan Inc. decided it was a good idea to raise the price of the life-saving EpiPen, which is used to stop a person from going into anaphylactic shock after experiencing an allergic reaction. Life-threatening allergies are on the rise and millions of people rely on the EpiPen to maintain their quality of
Taxotere is the synthetic version of Taxol. It is manufactured by Sanofi-Aventis and used to treat a variety of cancers. Taxotere cancer treatment drug and permanent hair loss lawsuits have been filed by numerous plaintiffs in multiple states are related to its use for breast cancer. The drug has been aggressively used by physicians to
This equivocates to roughly one out of 49-50 women needing surgery to repair or remove the device. Dr. Sedrakyan also added that the “surgery is likely to be much more complicated than the laproscopic approach that they should be considering. For its part, the FDA has acknowledged the study, releasing a statement saying “This is a high priority issue for the agency. The FDA plans to review the findings of this study, along with the latest medical literature on the Essure device and input from panel members and the public during our recent advisory committee meeting, to determine what future actions may be appropriate.” The FDA has not indicated, however, that it is planning on pulling the device from the market.
Congressman Fitzpatrick’s law simply reads: “Not later than 60 days after the date of enactment 8 of this Act, the Commissioner of Food and Drugs shall issue an order under section 515(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e(e)) withdrawing approval for Essure System.” Essure Problems is also asking others who have experienced complications from the device to also send their Representatives this letter (which is provided in Word Doc. Format at the bottom of the page).
We have the answers for you panel members, we have the answers for you FDA, all you have to do is ask us and we will show you. I am not a doctor, I am a metal smith. But that does not make my knowledge of Essure less real, it doesn’t make our knowledge or our information untrue. We can present to you allergy reports, operative notes, toxicology reports, blood work, x-rays, CT scans, MRIs, radiology reports, we have the medical information right in our hands.
After the intense discussion and testimony, the FDA panel recommended that more data be collected regarding skin allergies and other symptoms, as well as demanding that doctors need to be trained more thoroughly on how to implant and remove the device, although stopping short of demanding that Bayer recall the product.
Although no formal decisions will be made at Thursday’s meeting, the experts will consider whether or not to require a warning label on the product and if more clinical studies are needed to ensure the safety of the device.
Dr. Califf, a cardiologist, has been serving as the FDA’s deputy commissioner for medical products and tobacco since he joined the agency in February, divesting interest in his pre-FDA activity. Although he has donated his proceeds from private industry to nonprofit groups since the mid-2000s, Dr. Califf has taken some form of financial support from over 20 companies according to a disclaimer added to the end of a European Heart Journal article he penned last year. His financial disclosure form for 2014 alone lists consulting fees provided to him from seven companies, and his salary at Duke was funded in part by drugmakers Merck, Novartis and Eli Lilly.